Tony Coles, Cerevel CEO

Cerev­el blames Covid for de­layed neu­ro­science stud­ies, says pres­i­dent is leav­ing

Neu­ro­science biotech Cerev­el Ther­a­peu­tics said da­ta read­outs for sev­er­al clin­i­cal tri­als will come lat­er than orig­i­nal­ly ex­pect­ed, and al­so dis­closed the up­com­ing de­par­ture of its pres­i­dent, Abra­ham Ceesay.

The af­fect­ed tri­als in­clude a Phase II in fo­cal epilep­sy for dari­ga­bat, three Phase III tri­als for tava­padon in Parkin­son’s and a Phase IIa of CVL-871 in de­men­tia-re­lat­ed ap­a­thy. The epilep­sy tri­al will read out some­time af­ter 2023, the com­pa­ny said. Da­ta had been ex­pect­ed in mid-2023. An­oth­er Phase II for dari­ga­bat will start next quar­ter in pan­ic dis­or­der.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.